4//SEC Filing
Bashan Dror 4
Accession 0001415889-25-023700
CIK 0001006281other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 5:00 PM ET
Size
9.1 KB
Accession
0001415889-25-023700
Insider Transaction Report
Form 4
Bashan Dror
DirectorPRESIDENT AND CEO
Transactions
- Award
Common Stock
2025-09-03+195,000→ 2,344,418 total(indirect: By Trust) - Award
Stock Option (Right to Buy)
2025-09-03+340,000→ 340,000 totalExercise: $1.64Exp: 2035-09-03→ Common Stock (340,000 underlying)
Holdings
- 132,516
Common Stock
Footnotes (4)
- [F1]Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
- [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
- [F3]The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
- [F4]Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001781450
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 5:00 PM ET
- Size
- 9.1 KB